Close

Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference Apr 3, 2024 08:00AM
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update Mar 11, 2024 07:15AM
Lexicon Pharmaceuticals to Participate in The 22nd Annual Needham Virtual Healthcare Conference Apr 17, 2023 04:00PM
Lexicon Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference Apr 7, 2022 08:00AM
Lexicon Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference Apr 8, 2021 04:35PM
View Older Stories

Jul 21, 2020 09:30AM Pre-Open Movers 07/21: (NBEV) (LXRX) (OMI) Higher; (ACAD) (PIRS) (CTSO) Lower (more...)
Apr 2, 2019 07:00AM Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
Feb 27, 2018 04:30PM Lexicon Pharmaceuticals to Present at Upcoming Investor Conferences
Feb 23, 2018 07:14AM Needham & Company Downgrades Lexicon Pharmaceuticals (LXRX) to Hold
Apr 3, 2017 07:00AM Lexicon To Present At The 16th Annual Needham Healthcare Conference
Mar 6, 2017 07:53AM Lexicon Pharma (LXRX): Xermelo Today And Lining Up Catalysts Throughout the Year - Needham
Mar 1, 2017 07:00AM Needham and Company Reiterates Buy Rating and $21 PT on Lexicon Pharmaceutical (LXRX) Following FDA Approval of XERMELO
Dec 21, 2016 12:42PM Needham & Company Reiterates Bullish View on Lexicon Pharmaceuticals (LXRX) Following Phase 3 Trial Results
Sep 9, 2016 11:22AM Needham & Company Positive on Lexicon Pharma (LXRX) Following Sotagliflozin Phase 3 Data; Affirms at 'Buy'
Jun 24, 2016 11:13AM Needham & Company Weighs in on Brexit Biotech Impact (ACAD) (GILD0 (ICPT) (SGEN)
Apr 7, 2016 04:01PM Lexicon To Present At The 15th Annual Needham Healthcare Conference
Aug 3, 2015 10:42AM Lexicon Pharmaceuticals (LXRX) Bullish Stance Reiterated at Needham & Company Following Positive Telotristat Phase 3 Results
Jul 1, 2015 09:44AM Needham & Company Reiterates Buy Ahead of Lexicon Pharma (LXRX) Phase 3 Rsults
Apr 9, 2015 08:00AM Lexicon To Present At Needham & Company's 14th Annual Healthcare Conference
Nov 21, 2014 06:21AM Lexicon Pharma (LXRX) Prices $50M Common Stock Offering
Nov 19, 2014 04:02PM Lexicon Pharma (LXRX) Reports $50M Stock Offering
Apr 29, 2013 02:00PM Unusual 11 Mid-Day Movers 04/29: (OSH) (WRLS) (GALT) Higher; (LAS) (NTE) (GWAY) Lower
Dec 31, 2012 12:58PM Unusual 11 Mid-Day Movers 12/31: (UNXL) (DUF) (LXRX) Higher; (EMITF) (CALM) (ZAZA) Lower
Oct 12, 2012 01:29PM Unusual 11 Mid-Day Movers 10/12: (NINE) (GLUU) (NPSP) Higher; (AEZS) (OCZ) (TZOO) Lower
Oct 12, 2012 09:36AM Pre-Open Movers 10/12: (LXRX) (IGTE) (STM) Higher; (AEZS) (AMD) (WFC) Lower (more...)
Aug 1, 2012 08:45AM Needham & Company Reiterates a 'Buy' on Lexicon Pharmaceuticals (LXRX); Conference Call Takeaways
Jul 18, 2012 11:21AM Needham & Company Maintains a 'Buy' on Lexicon Pharmaceuticals (LXRX); Big Pipeline Undervalued
Jun 22, 2012 07:46AM Needham & Company Reiterates a 'Buy' on Lexicon Pharmaceuticals (LXRX); LX4211 Phase 2b Trial Data Expected Soon
Jan 6, 2012 10:13AM Needham & Company Reiterates a 'Buy' on Lexicon Pharmaceuticals (LXRX); 2012 Preview: Several Key Clinical Milestones Anticipated
Dec 23, 2011 07:35AM Needham & Company 2012 Biotech Preview
Nov 2, 2011 08:20AM Needham & Company Reiterates a 'Buy' on Lexicon Pharmaceuticals (LXRX); Q3 Review
Sep 22, 2011 02:23PM Needham & Company Maintains a 'Buy' on Lexicon Pharmaceuticals (LXRX); Underappreciated Given Number of Phase 2 Compounds Under Development
Aug 10, 2011 08:25AM Needham & Company Reiterates a 'Buy' on Lexicon Pharmaceuticals (LXRX); Encouraging Phase 2 LX1032 Results in Sandostatin-Treated Carcinoid Syndrome Patients
May 27, 2011 07:45AM Needham & Company Starts Lexicon Pharmaceuticals (LXRX) at Buy; Valuation is Attractive
View Older Stories